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Abstract
There is a fairly consistent, albeit non-universal body of research documenting cognitive declines
after cancer and its treatments. While few of these studies have included those 65 and older, it is
logical to expect that older patients are at risk of cognitive decline. In this paper, we use breast
cancer as an exemplar disease for inquiry into the intersection of aging and cognitive effects of
cancer and its therapies. There are a striking number of common underlying potential biological
risks and pathways for the development of cancer, cancer-related cognitive declines, and aging
processes, including the development of a frail phenotype. Candidate shared pathways include
changes in hormonal milieu, inflammation, oxidative stress, DNA damage and compromised DNA
repair, genetic susceptibility, decreased brain blood flow or disruption of the blood-brain barrier,
direct neurotoxicity, decreased telomere length, and cell senescence. There are also similar
structure and functional changes seen in brain imaging studies of cancer patients and those seen
with “normal” aging and Alzheimer’s disease. Disentangling the role of these overlapping
processes is difficult since they require aged animal models and large samples of older human
subjects. From what we do know, frailty and its low cognitive reserve seem to be a clinically
useful marker of risk for cognitive decline after cancer and its treatments. This and other results
from this review suggest the value of geriatric assessments to identify older patients at the highest
risk of cognitive decline. Further research is needed to understand the interactions between aging,
genetic predisposition, lifestyle factors and frailty phenotypes to best identify the sub-groups of
older patients at greatest risk for decline and to develop behavioral and pharmacological
interventions targeting this group. We recommend that basic science and population trials be
developed specifically for older hosts with intermediate endpoints of relevance to this group,
including cognitive function and trajectories of frailty. Clinicians and their older patients can
advance the field by active encouragement of and participation in research designed to improve
the care and outcomes of the growing population of older cancer patients.
Introduction
Cancer is largely a disease of older age. 1 With the graying of America, one in five
individuals will be 65 years or older (“older”) by the year 2030. 2 As these individuals
develop cancer, they are at risk of experiencing adverse cognitive effects of this disease and
its local and systemic therapies. Cancer-related cognitive declines were first described three
decades ago, 3 and a fairly consistent, albeit not universal, picture of these deficits has
evolved to the present. 4–6 There are a striking number of common underlying biological
risks and pathways for the development of cancer and cancer-related cognitive declines and
aging processes. These commonalities may have implications for the clinical care of the
growing number of older cancer patients. 5,7–13
Breast cancer is an ideal disease for inquiry into the intersection of aging and cognitive
effects of cancer and its therapies because it is the second most common cancer in
women, 14 with more than 50% of new cases occurring among women 65 and older, 1,15 and
its treatment has historically included a high rate of use of systemic chemotherapy and/or
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hormonal therapy. There is also the largest body of empiric evidence about the cognitive
aspects of breast cancer and its treatments, compared to other cancers.
Most controlled investigations and meta-analyses of the studies of the effects of breast
cancer therapy on cognitive function report decrements in one or more domains, including
verbal working memory, visual memory and visual-spatial domains, executive function
(including working memory), and/or processing speed compared to pre-treatment, cancer
and/or population controls. 5,6,16–21 These cognitive declines have been observed to persist
for variable periods of time from one 16,22 to as many as 10–20 years post-treatment. 23–25
Unfortunately, the mean age in the most recent meta-analysis of the cognitive effects of
breast cancer therapy was 53 years 6 and only a few studies have been designed to examine
outcomes for older patients.4,26–29
High rates of objective and subjective cognitive impairment have been reported in most
studies of older breast cancer patients. 28–30 However, variable rates of cognitive decline
have been noted in other studies that include older cancer patients. 4,27,31–34 All of these
reports have had small samples of older patients (range of n=13–50), 4,27,30 some have
focused on patients treated in mid-life and evaluated at age 65 or older 28 and only one was
able to examine age interactions. 7 In that study, Ahles and colleagues found that women
ages 60 to 70 with low baseline cognitive reserve that underwent chemotherapy had lower
performance on tests of processing speed compared with those not receiving chemotherapy
and controls (Figure 1). 5,7 Thus, it is possible that only a sub-group of older patients (or
patients at any age) experience cognitive effects after systemic cancer therapy. 6,7,35
However, there is only limited empiric evidence about the risk factors that define vulnerable
groups, and even less for older cancer patients.
In this paper, we present a framework for considering the relationships among the key
constructs involved in evaluating the cognitive effects of cancer and its treatments at the
intersection of aging, review some potential shared biological mechanisms and how they fit
within current theories of aging, discuss methodological challenges in conducting research
on this topic in the older population, and summarize the clinical implications of these results
for the care of the growing older population diagnosed with and surviving with cancer.
Aging, Frailty, and Cognitive Decline
Aging is the net effect of the temporal accumulation of damage to cellular processes and
systems, loss of compensatory mechanisms, and increased vulnerability to disease and
death. Closely aligned to this definition is the clinical concept of frailty, which can be
considered a phenotype of aging. This phenotype is characterized by a diminished biologic
reserve and resistance to stressors caused by collective declines across physiologic systems,
leading to vulnerability to insult and adverse outcomes. 36
Fried and her colleagues initially described the frail phenotype as having three out of five of
the following criteria: weight loss, exhaustion, low physical activity, slow walking gait, and
poor grip strength. 36 Although this original phenotype did not include cognitive function, it
is now widely recognized as one of the key factors involved in the impaired physiologic
pathways leading to frailty. 37–40 The converse is also true: individuals with frailty are more
vulnerable to the development of cognitive disorders (e.g., Alzheimer’s disease) and to
cognitive decline after stressors such as cancer therapy (Figure 2). 7,24,41 Further, frailty and
cognitive deficits each are independently associated with high risks of dependence and
mortality. For instance, selected measures of cognitive function, such as the Trail Making
Test, have been noted to predict physical frailty as measured on the Short Physical
Performance Battery, as well as mortality in older individuals in the general population. 42
Identifying the biological underpinnings of these associations and disentangling their
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temporal and etiological relationships is an important research priority and an area of
nascent discovery.
From what we do know, it seems that there are several potential common pathways.
Observations that biomarkers of inflammation such as high C-reactive protein (CRP) and
high interleukin-6 (IL-6) are seen in the frail phenotype, 43 senescence, 9,44,45 and cognitive
declines in Alzheimer’s disease 46 and after cancer therapy 22,47 suggest one potential
common biological pathway. There is also overlap in the genotypes (e.g., APOE
polymorphisms) associated with cancer related cognitive declines, Alzheimer’s and their
associated frailty phenotypes. 24,48–50 Further support of the concept of common underlying
biological processes is based on the recent body of evidence demonstrating similar brain
structural alterations in aging, cancer-related cognitive declines, and Alzheimer’s disease,
including decreases in overall brain volume, gray matter, white matter connectivity and
hippocampal volume. 5,13,25,51–54 Finally, the observation that cancer patients have lower
cognitive function than expected based on age and education even before any treatment 5,55
suggests, as depicted on Figure 3, that there are common underlying risks for cancer and
cognitive decline, and that both are in part age-related phenomena. In the next section we
highlight some of the research on the potential common pathways related to the
pathogenesis of cognitive decline, frailty and aging.
Common Biological Pathways
Most consider that cancer and aging are linked, although the molecular mechanisms
responsible for the increasing risk of cancer with increasing age and frailty are not
completely understood. Aging is clearly related to neurodegenerative diseases such as
Alzheimer’s disease. It is also biologically plausible that cancer and neurodegenerative
conditions are linked, since they have some common pathways related to the cell cycle (e.g.,
p53 proteins and the Pin1 protein), albeit in opposing directions, with cancer related to
proliferation and Alzheimer’s related to cell death. 56–58
In this broad context, the precise biological mechanisms and pathways underpinning
cognitive decline after cancer and/or its treatments remain uncertain. The common
“candidate” pathways include changes in hormonal milieu, inflammation, oxidative stress,
DNA damage and compromised DNA repair, genetic susceptibility, decreased brain blood
flow or disruption of the blood-brain barrier, direct neurotoxicity or damage to specific brain
regions, decreased telomere length, and cell senescence (Figure 3). 5,8,51,59–62
Hormones
Hormonal levels decrease over the lifespan and have been implicated in cognitive function
in non-cancer populations 63 and hormonal replacement therapy has been noted to decrease
the risk of Alzheimer’s disease by up to 29%. 64–69 Breast cancer hormonal therapies act by
blocking or lowering hormonal levels in individuals with estrogen receptor positive tumors.
Possible mechanisms by which hormonal treatment could affect cognition include decreases
in cholinergic activity 66,70, reduced induction of serotonin receptors,71 direct toxic effects
on dendrites and synaptic connectivity,72,73 and changes in lipids.74 Since estrogen also has
anti-oxidant effects 75,76 and maintains telomere length 77, breast cancer hormonal therapies
that block estrogen may also exert their negative effects on cognition via accelerating aging.
The role of hormonal change is supported by the body of research demonstrating decrements
in cognitive function among women receiving systemic hormonal therapy, either alone or
with chemotherapy. 78–83 However, effects are not universal and may not be observed with
all hormonal therapies. For instance, a recent clinical trial reported by Schilder and her
colleagues noted cognitive declines in verbal memory and executive function among women
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treated with tamoxifen but not exemestane. 79 This result is biologically plausible since
estrogen can be neuroprotective and estrogen receptors, the target of tamoxifen and other
drugs in its class, are found in large numbers in the frontal lobe and hippocampus; 84–87
these same areas have been noted to have abnormalities on imaging studies. 53,88 In contrast,
exemestane, one type of aromatase inhibitor, blocks conversion of androgens into estrogens,
and its metabolites have mild androgenic properties. Since androgens can enhance cognition,
this may be one explanation for the relative lack of impairment due to this particular
hormonal regimen. However, results for the effect of other hormonal therapies on cognition
have been inconsistent. 7980,81 One intriguing result of the Schilder trial comparing
hormonal therapies was a preliminary result that tamoxifen had larger effect sizes and
affected a greater number of cognitive domains in women 65 and older compared to women
less than 65 years of age. 79 It will be important to replicate this finding and to examine the
role of different types of estrogen receptors in brain tissue, especially if hormonal therapies
will be recommended for longer periods of administration..
Inflammation
Inflammatory responses involved in aging, cancer and/or generated by cancer-directed
agents have been suggested as one pathway for cognitive declines via triggering of
neurotoxic cytokines. 89 A study by Ganz and colleagues examined several pro-
inflammatory cytokines in breast cancer patients. They found that soluble tumor necrosis
factor-alpha receptor II (sTNF-RII) was significantly higher in those who received
chemotherapy compared to those who did not, but that levels declined over time. Of note,
the higher sTNF-RII levels were associated with self-reported memory complaints and
decreased brain metabolism in frontal regions on positron emission tomography (PET)
scans, and subjective cognitive function improved as sTNF-RII levels declined over the one
year of follow-up. 22 Other inflammatory cytokines were not associated with neurocognition
and the relationships were not significant after controlling for fatigue levels, suggesting that
fatigue and cognitive declines might both share a common inflammatory etiology.
Unfortunately, assessments occurred after initial therapy, so that the separate effects of
having cancer could not be assessed; the study also lacked a control group and was focused
on the effects of menopause and hormonal therapy in younger women, so may not be
generalizable to pathways related to aging. Also, since aging is associated with the
accumulation of multi-morbidities that affect or are the result of inflammatory pathways
(e.g., diabetes, heart disease), 90 it will require careful sampling and sub-group analysis to
segregate the impact of inflammation related to cancer in studying cognitive outcomes and
to control for fatigue components of frailty phenotypes. This will be an important area for
future research.
DNA Damage and Repair
Oxidative DNA damage, as measured in lymphocytes, has been noted in breast cancer
patients both before any systemic therapy and after chemotherapy. 13,91,92 Conroy and her
colleagues recently conducted an innovative study with breast cancer survivors and matched
non-cancer controls. The sample ranged in age from 41 to 79 years old; the cancer patients
were three to 10 years post-treatment. They found that oxidative DNA damage was higher in
patients than controls and that DNA damage was correlated with self-reported cognitive
problems, lower cognitive function and less frontal gray matter density and brain activation
on functional MRI (fMRI). 13 While only small numbers of patients were assessed (n=48),
the result is interesting because oxidative DNA damage and diminished DNA repair
mechanisms are also markers of senescence, 44 and are seen in age-related diseases
including Parkinson’s disease, mild cognitive impairment, and Alzheimer’s disease. 93,94
Hormonal therapies may also be associated with increased DNA damage. 95 The exact
mechanisms and pathways whereby DNA damage leads to cognitive decline is unclear, but
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it is postulated to be related to either production of defective proteins that lead to neuronal
apoptosis 96 or problems in transcription that cause the loss of required gene protein
products. 97 It should also be noted that DNA damage can trigger cytokine release, which in
turn increases oxidative stress and further DNA damage. 98,99 How these processes are
affected by age-related DNA damage or chronic inflammation related to other non-cancer
comorbidities is unclear and will need to be disentangled to fully understand mechanisms of
cognitive decline in older cancer patients.
Genetic Factors
There is considerable variability across individuals in presence and extent of cognitive
changes associated with cancer and cancer treatment. The observation that a subgroup of
patients appears differentially affected strongly suggests that genetic influences may
modulate the influence of exposure to cancer pathophysiology or treatment. 12,51,100
Polymorphisms of the APOE and COMT genes have been studied for associations with
cognitive changes after cancer treatment 21,24 but numerous other candidate genes may play
a role. 51,100 Many of these genes have a role in age-related cognitive decline.
APOE is located on chromosome 19 and was first identified as a risk for Alzheimer’s
disease in the early 1990’s, 101 and it remains the leading known genetic risk for this
disease. It codes for apolipoprotein E (ApoE), a complex lipoprotein known to play a role in
lipid transport and regulation of inflammatory immune activity, among other biological
functions. In the central nervous system, ApoE is also involved in amyloid beta metabolism,
a key substrate of Alzheimer’s, as well as neural repair processes after brain injury and brain
plasticity. APOE has three alleles (ε2, ε3 and ε4 variants) which are, in turn, determined by
two single nucleotide polymorphisms (SNPs) - rs7412 and rs429358. APOE ε4 is the
adverse risk allele that confers risk of Alzheimer’s 102 and is associated with poor recovery
after stroke and trauma. 103,104
Ahles and colleagues noted that breast cancer survivors who received chemotherapy and
were APOE ε4-positive had greater cognitive decline in the visual-spatial and visual
memory domains compared to ε4-negative survivors receiving this treatment (average age
56).24 However, the relationship between APOE and cognitive outcomes has not been
consistent in the few other studies to examine this question among breast cancer patients, 54
although they were often not designed to have power to detect genetic influences. APOE has
also been noted to be a risk factor for the development of breast cancer 105 or a moderator of
fat and obesity risks of breast cancer. 106 If APOE polymorphisms are linked to risk of
disease, especially more aggressive types of disease or larger tumors (seen in obese women),
and women with these tumors are differentially more likely to receive chemotherapy, then
APOE-post treatment relationships may be confounded.
Adding to the complexity are the observations that polymorphisms of estrogen receptors
also influence ApoE synthesis 107,108 and interact with ApoE in risk for Alzheimer’s, 109 so
there may be treatment-gene interactions in producing cognitive decline. This idea is
supported by one study of non-cancer patients where hormone replacement therapy was only
protective of cognitive decline among women without an ApoE ε4 allele. 110 It will be
important to test these hypotheses directly in future studies of cognitive outcomes in older
breast cancer patients receiving different types of hormonal therapy, especially as
recommendations for this modality are extended from five to ten years of treatment. 111,112
The other gene studied specifically in cancer patients with regard to cognitive outcomes is
COMT, located on chromosome 22q11. COMT codes for catechol-O-methyltransferase, an
enzyme that metabolizes catecholamine neurotransmitters including dopamine, epinephrine,
and norepinephrine; the Val158Met SNP (rs4680) in COMT (substitution of methionine with
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valine) increases dopamine break down and decreases synaptic neurotransmitter levels.
COMT plays an important role in dopamine regulation in the frontal lobes and has been
shown to be associated with executive function in normal controls. In a study of cancer and
cognition by Small and colleagues, breast cancer patients treated with chemotherapy who
were COMT-valine carriers performed worse on measures of attention compared to COMT-
methionine homozygotes, although the average age of these women was 51. 21 Of note,
Lindenberger has found an age interaction with the COMT gene. 113
Brain-derived neurotrophic factor (BDNF) is another gene involved in neuron growth and
repair and is found primarily in the prefrontal cortex and hippocampus. 114,115 A functional
polymorphism of BDNF has been associated with lower memory and executive function in
non-cancer populations. 116–118 Lindenberger and colleagues observed interactions between
BDNF, COMT, and age. 113 This result underscores the complex interplay between aging,
declining reserve and genetic factors. Overall, the role of BDNF and other neural and glial
growth factors appears promising for investigation in cancer patients.
Some other single nucleotide polymorphisms (SNPs) have also been implicated in cognitive
decline among cancer patients. In a preliminary report, Ganz reported that the TNF-
alpha-308 promoter SNP was associated with the level of self-reported memory problems
after cancer treatment, 119,120 consistent with the posited role of an inflammatory
mechanism in the etiology of this syndrome.
Variations in genes that affect blood-brain barrier transporter could also be involved in
mediating the direct neuro-toxicity of some chemotherapeutic agents, since in animal
models, only small doses are needed to produce neuronal cell death. 51,61,121 For example,
the multidrug resistance 1 (MDR1) gene encodes the protein P-glycoprotein (P-gp); P-gp
influences the level of a chemotherapeutic agent in the brain. 51,122 Polymorphisms of the
MDR1 gene (e.g., C3435T in exon 26) 123 could influence P-gp function such that a
sufficient amount of drug reaches neuronal cells to directly cause toxicity.
An emerging area of genetic investigation is related to microRNAs (miRNA). miRNAs are
very small non-coding RNAs that are becoming increasingly recognized as playing a major
role in regulating gene expression and cell metabolism in cancer and neurodegenerative
disease. 48 Holohan recently examined the relationship between the functional roles of
miRNAs in cancer and Alzheimer’s disease as two age associated disorders. 48 Numerous
other candidate genes and pathways are thought to potentially may play a role in cognitive
changes associated with cancer and cancer treatment and have been reviewed
previously. 51,100
Alterations in Blood-Brain Barrier and other Vascular Factors
Many systemic chemotherapies including anthracyclines do not appear to cross the blood-
brain barrier. Exceptions may include those included in the cyclophosphamide, methotrexate
and fluorouracil (CMF) regimen.89,124 Since older patients may remain more likely to get
CMF regimens due to the higher cardiac and other toxicity profiles seen with anthracycline
regimens, older breast cancer patients may be at higher risk for direct neurotoxicity,
underscoring the need to carefully consider specific agents when studying outcomes among
older patients.
Other factors that affect vascular function125 have been implicated in aging and cognitive
performance, such as smoking and low levels of high density lipoproteins (HDL).100,126,127
Interestingly, nicotine and statin medications seem to be protective of cognitive decline, so
that these relationships are not straightforward.125,128 Similar to observations in cancer
patients, there also appear to be interactions between cerebrovascular disease or diabetes and
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the ApoE ε4 allele in producing memory impairments.17,18,129 These observations could
help to identify subgroups of older cancer patients at risk for cognitive declines related to
vascular factors.
Structural and Functional Brain Changes on Neuroimaging
To the extent that cancer treatments may accelerate or mimic the effects of aging, some
overlap in brain structures affected by cancer treatments and aging is expected. Imaging
studies have demonstrated that total gray matter volume reliably decreases with advancing
age, with regional changes exhibited mainly in the frontal cortex and in regions around the
central sulcus, including the hippocampus. 130 Lower hippocampal volume is related to
memory functioning and has been observed in breast cancer patients after treatment. 131
White matter also diminishes with increasing age. 130,132 Reduction in volume of frontal
brain structures and changes in the integrity of white matter tracts have been reported after
chemotherapy, as have alterations in brain activation on functional
neuroimaging. 12,13,25,133–139 Of note, there appear to be pre-treatment cancer effects as
well, with altered frontal cortex activation during fMRI tasks in breast cancer patients
relative to healthy controls. 140,141 Similar abnormalities related to breast cancer treatment
have been observed using functional positron emission tomography (PET) and electro-
physiological methods. 142 There are also differences in resting state between breast cancer
patients and controls. 143 However, all of these imaging studies have been among breast
cancer patients under age 65. Imaging studies in older patients will be critical to confirming
the brain structural links between cancer and aging.
Telomeres
Over the life course, telomeres shorten with each cell replication, ultimately leading to cell
senescence (see below) and apoptosis, so that leukocyte telomere length has been used an a
marker of cellular age with shorter length indicating a greater degree of senescence. As
such, telomere health has been linked to aging, Alzheimer’s disease severity, cancer risk,
and mortality rates.144 For instance, patients with Alzheimer’s have been observed to have
shorter telomeres than controls, and shorter length has also been associated with greater
disease severity.144 Cancer chemotherapy also has effects on telomere length, and this could
be another common pathway between aging and cancer related cognitive decline via effects
on replicating cells. 62,145–147
Senescence
Senescence refers to the state of cells that are metabolically active but can no longer
replicate. Many of the same factors that we have been discussing as common potential
causal pathways to aging and to cognitive decline after cancer and cancer therapy have been
implicated as stressors that can lead to cell senescence. 8,148 Senescent cells evoke
inflammatory responses and accumulate at sites of pathology, including Alzheimer’s
plaques. 8,148 Senescent cells can also be considered a biomarker of the frailty phenotype 9
that places cancer patients at risk for cognitive declines. The targets for cancer treatments
could potentially negatively affect biologic markers of aging such as senescence, since there
is a reciprocal relationship between tumor suppression and senescence in healthy cells. For
instance, increases in tumor suppressor mechanisms through p53/p21 and p16INK4a/pRB
and other pathways are under investigation as leverage points for treat cancer but are
associated with increased cell senescence, and could therefore accelerate aging and increase
risk for cognitive toxicity. 8,148 Thus, it will be important to consider senescence and the
translation of the basic science of aging into clinical studies of the impact of cancer and new
systemic cancer therapies on cognitive outcomes in older patients.
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Taken together, this body of mechanistic research suggests that biologic processes
underlying cancer, the impact of cancer treatments, aging, and cognitive decline are linked,
and that cancer treatments may actually accelerate the aging process. 62 As with most
conditions, not all breast cancer patients develop cognitive effects related to their cancer or
its treatments, underscoring the need to identify the sub-group with the highest risk of
cognitive decline. Overall, age-related phenotypes such as frailty and diminished cognitive
and overall reserve and biomarkers reflecting senescence and aging processes are logical
candidates for identifying patients at high risk of cognitive decline. 5
Models of Aging
The constellation of intersecting factors related to cancer-related cognitive decline, frailty,
and aging raises several provocative questions: If cancer therapy impacts cognitive function,
does the trajectory of dysfunction parallel that of normal aging (phase shift hypothesis), or is
the trajectory of dysfunction accelerated in comparison to normal aging (accelerated aging
hypothesis)? 5 Is the lowest common denominator a depletion of reserve leading to a frail
phenotype (reliability theory of aging)?
As depicted on Figure 4, the phase shift theory postulates that cancer patients experience
decrements in cognitive function compared to their non-cancer counterparts, and those
decrements remain constant over time. Alternatively, if cancer and its treatment are actually
accelerating aging processes, we would expect the slope of decline in cognitive function
would be steeper for patients relative to their non-cancer cohorts. The relativity theory of
aging 149 further posits that declines in cognitive function are a function of overall system
redundancy and repair (i.e., net reserve), so that patients who are frail would be expected to
show the steepest decline and those with less frailty (and greater reserve) would decline at a
slower rate. These differences would not be appreciated by only examining the average
trajectory (see also Figure 2). Beyond cancer and cancer therapies, access to healthcare and
management of chronic disease and lifestyle factors such as exercise or smoking would
affect reserve and system failures. In the reliability theory, frailty would be considered as the
failures of multiple systems.
An important strength of the reliability theory for studying cognitive effects of cancer and its
treatments in older patients is that it does not depend on a given treatment affecting a
specific biologic pathway. 5 As noted by Ahles and colleagues, different patterns of failure
across various biologic systems may confer more or less risk of specific treatments for each
patient: one patient may be vulnerable to DNA damaging effects of a particular
chemotherapy regimen, whereas another patient may be susceptible to the impact on the
hormonal milieu of endocrine treatments. Implicit in this conceptualization is the idea that
the trajectories of cognitive decline are dependent on pre-morbid cognitive and other system
reserve. One practical implication for future research is the need for pre-treatment
assessments and evaluation of self-reported function prior to cancer diagnosis. Viewed
through the lens of aging theories, researchers may also want to specifically investigate
discrete trajectories, rather than group averages when assessing temporal trends in cognitive
function. 150
Measurement Issues
There are many methodological considerations in studying the complex interactions between
cancer, cancer therapy and cognitive function. In this section we highlight several concerns
specific to evaluations of the role of aging and needs of older patients. For excellent reviews
of international consensus panels on methods for studying cancer and cognition the reader is
referred to summaries of the International Cognition and Cancer Task Force. 35,142,151
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First, this is a field that will require transdisciplinary collaboration between basic scientists
and clinical researchers, including gerontologists and geriatricians. One obvious
methodological basic science issue is the need to use older animals or systems that mimic
aging systems, since the aging tissue microenvironment can have important effects on age-
related chronic disease phenotypes and cognitive processes. 9 Kirkland has suggested use of
chronologically-aged mouse chronic disease models, progeroid bred with chronic disease
mouse models, or chronic disease mouse models treated with “age accelerating”
interventions such as high fat diets. 9
Likewise, in human studies, the greatest challenge to understanding the complex interplay of
cancer and its therapy against the backdrop of aging processes is the lack of inclusion of the
older age group in many research studies and clinical trials. As noted in the preceding
sections, it will be important to include sufficient numbers of older patients to capture
variability in reserve and frailty, effects of different classes of therapeutic agents, and the
impact of other chronic diseases and biological processes.
To fully understand the trajectory of cognitive declines, it is also essential to assess baseline
function and follow patients longitudinally. A well-matched non-cancer control group is also
essential to valid inference, but can be difficult in older populations given the high rates of
cognitive disorders and other chronic diseases and medications that affect cognition. Thus,
well specified inclusion criteria and matching based on multi-morbidities should be
considered. Care must be taken to use instruments that are validated in the target population.
Moreover, issues of “cognitive reserve” 7,152 must be taken into account through appropriate
control for estimated premorbid ability, educational attainment, and other proxy measures of
this construct. Although many investigators strive for abbreviated cognitive assessments
with older patients, in part because of the need to avoid potential fatigue effects from longer
test batteries, it is critical that the brevity is balanced by an adequate evaluation of the
cognitive domains hypothesized to be impacted by treatment (Table 1).
Recruiting older participants also requires sensitivity to needs of this group, including the
need for larger fonts, hearing and ambulatory assistance, pacing of testing sessions, and
having protocols to address research-detected cognitive decline.
To the extent feasible, studies should include frailty measures and other markers of age-
related processes and biospecimens for correlative science analyses to elucidate biologically
plausible mechanisms specific to older hosts (e.g., markers of cell senescence).
Analyses of data from older patients could consider use of trajectory analysis 153 in addition
to use of group means and changes in group means. Informative missing data on covariates
and cognitive outcomes as well as the impact of practice effects will be especially important
to consider when following older age groups longitudinally. As in other observational
research, the analysts will need to consider the role of confounding due to the common
factors affecting systemic treatment selection and those placing older women at risk for
cognitive declines.
Across a variety of cancers and types of treatment, the magnitude of cognitive effect tends to
vary by choice of control group; this has not been empirically evaluated in older patients,
but should be even more important than in studies of younger patients. For instance, in
several meta-analyses, the largest effects (medium to large effects based on SD-effect sizes)
were noted when cancer patients were compared to population normative values; moderate
changes were seen when patients were compared to healthy non-cancer controls matched on
age and education. 17,18,20,154,155 In studies of younger breast cancer patients, effects appear
to be the smallest when patients are compared to their own baseline, pre-treatment
function, 154 although practice effects may account for some of the lack of effect if
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alternative forms of tests are not employed. As suggested by Ahles, Wefel and others, these
average effects may mask meaningful declines among sub-groups. As they note, when
declines in performance are combined with improved performance as a result of practice for
the majority of patients, the effect of chemotherapy on cognitive declines may be
underestimated. 34,156
Practice Implications
From the preceding review it is apparent that there is a fairly strong body of evidence
linking aging processes to cancer-related cognitive declines. But it is also clear that there are
many unanswered questions. While the research community grapples with how to provide
rigorous empiric evidence for older cancer patients, clinicians are faced every day with
caring for the growing number of older cancer patients presenting to their practices. What
then are the implications of what we think we know about cancer-related cognitive decline
for the care of older breast (and other) cancer patients?
The obvious implication for oncology training is that it includes education on geriatric
assessment and that geriatric assessments should be part of routine care since they can
provide information on frailty phenotypes and reserve. 157 The results of geriatric
assessment could be used as a tool for identifying sub-groups of older patients who are
likely to be at highest risk for cognitive decline after systemic therapy. This information
could be used together with clinical data and results of tumor multi-gene profiles in
discussions with patients about the balance of benefits and harms of systemic therapy.
Geriatric assessment data could change treatment recommendations, especially when
indications for systemic therapy are equivocal, since cognitive changes are among the
symptoms most feared by older adults. 158–161
Geriatric assessment could also be used to identify the population of “pre-frail” older cancer
patients that might need close monitoring and intervention during and after cancer systemic
therapy. In addition, our review suggests that interventions that prevent frailty and maintain
function could be useful in preventing or ameliorating cognitive decline among cancer
patients.
There is a relative paucity of human studies designed to evaluate interventions to treat
cancer-related cognitive changes compared to the large body of literature describing the
phenomenon, although there are data from animal models that are informing new
approaches. Unfortunately, most studies in humans and animals have generally not included
or not been focused on older patients (or animals). 162 There are, however, studies in
Alzheimer’s disease with older patients that may have relevance to the cancer setting,
including behavioral and pharmacological interventions. Existing interventions have
reviewed elsewhere, 163 and are briefly summarized briefly.
One prominent behavioral approach is cognitive training. In younger cancer patients,
cognitive therapy, including rehearsing compensatory strategies was noted to improve
cognitive function, 164 but this effect was not noted in other studies. 165 Similar
interventions have also been successful in older Alzheimer’s patients. 166 A review of
factors associated with prevention of age-related cognitive decline reported evidence that
physical exercise and possibly diet could be efficacious behavioral interventions.166
Exercise has been protective of decline after chemotherapy in rodents. 167 Increasing
antioxidants via dietary change has been shown to be protective of cognitive decline in
animal models. 60 Interestingly, in preliminary trials with non-smoking, non-cancer patients
with mild cognitive impairment, transdermal nicotine was safe and improved cognitive
function, possibly via stimulation of nicotinic acetylcholine receptors. 168 These data
suggest the value of conducting trials to provide evidence to support incorporation of some
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of these approaches in to clinical care to preserve cognitive function in older cancer
survivors.
There are several promising pharmacological interventions that have been tested largely in
animal models.163 Fluoxetine have been shown in animal models to prevent behavioral and
hippocampal deficits associated with older chemotherapy regimens, such as 5-
Flourouracil. 169,170 These approaches have not yet been replicated in older animals,
translated to clinical settings with humans, or tested for safety or interactions with
chemotherapy efficacy. It will be important to include sufficient numbers of older patients
when these studies are conducted. In human research, two studies have demonstrated the
efficacy of modafinil, a psycho-stimulant, in improving memory and attention and reducing
fatigue in cancer patients. 171,172 Herbal compounds such as Gingko biloba are under
evaluation in ongoing cancer trials163 and Alzheimer’s treatment drugs have been examined
in patients undergoing brain irradiation.
Given the parallels between aging, frailty and cognitive decline in cancer patients, it is also
logical that interventions that prevent frailty could be useful as targets for older cancer
survivors. These “anti-aging” models have been examined largely in animal models and
include caloric restriction, rapamycin, protein aggregation inhibitors, and removal of
senescent cells. 9
As the validity of personalized medicine becomes more established, understanding the
genetic profiles of older patients at the greatest risk for cognitive decline could also be
useful in clinical decision-making about systemic therapy and risk of cognitive decline.
These data could also contribute to the next generation of pharmacogenetic studies that
investigate which medications best prevent cognitive effects in vulnerable women and which
systemic therapies are most and least likely to lead to cognitive toxicity in older
women. 173,174
Conclusions
There is a strong albeit non-universal body of literature supporting the phenomenon of
cognitive decline after breast cancer and its systemic therapies. This side effect is likely to
be only experienced by a sub-group of patients, and while risk factors have been identified,
biological mechanisms and pathways have not been fully elucidated. From what we do
know, it appears that there are common underlying processes at the intersection of cancer,
aging and the frail phenotype. Geriatric assessment could be a useful tool to aid in treatment
decision making and identify the sub-groups most vulnerable to adverse cognitive outcomes.
Given the demographic imperative of a rapidly growing older population, increasing cancer
incidence with advancing age and the increasingly chronic nature of breast cancer, research
in older cancer patients and survivors will be critical to providing the evidence for practice
guidelines.
Thus, we recommend that designing and conducting basic science and population trials
specifically for older cancer patients should receive high priority. These studies should
include intermediate endpoints of relevance to this group, including cognitive function and
trajectories of frailty. 175–177 Clinicians and their older patients can advance the field by
active encouragement of and participation in research designed to improve the care and
outcomes of older cancer patients.
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Change in Processing Speed by Treatment, Age group, and Cognitive Reserve Among
Breast Cancer Patients
Pre- to post-treatment change in processing speed by treatment, age groups, and level of
cognitive reserve (assessed by the Wide Range Achievement Test (WRAT)-Reading).
Reprinted with permission from Ahles et al 2012, Journal of Clinical Oncology 5
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Impact of Change in Brain Resources and Frailty Levels on Cognitive Performance by Age
The same change in brain resources can have a minimal effect on cognitive performance in a
young adult (a), a moderate effect in an older adult with high cognitive reserve (b) and a
greater effect on an older adult with low cognitive reserve (c). Likewise, the same change in
frailty level will have differential effects on the individual as a function of overall system
reserve.
Adapted and reprinted with permission from Ahles et al, Psychooncology 2012 24
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Postulated Common Underlying Aging Processes Associated with Frailty, Cancer and
Cancer Systemic Therapy and their Impact on Cognitive Outcomes
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Trajectories of Cognitive Decline Based on Theories of Aging and Frailty Phenotype
Adapted from Ahles et al, 2012 Journal of Clinical Oncology 5
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Table 1
Domains of Cognitive Function Frequently Affect by Cancer and Cancer Systemic Therapy and their
Implications for Daily Activities in Older Cancer Patients




Trailmaking Parts A & B, Digit Symbol, Controlled
Oral Word Association Test (COWAT), NAB Driving
Scenes, Timed Instrumental Activities of Daily Living
(TIADL), NAB Figure Drawing
Ability to organize activities, arrive on time, make
plans and decisions, correct errors and
conceptualize.
Attention NAB Digits Forward, NAB Digits Backward Ability to pay attention to new information and
process the information quickly.
Language Boston Naming Test, Category Fluency Ability to fluently bring words to mind.
Learning and Memory Logical Memory I and II Wechsler Memory Scale
(WMS-4), NAB List Learning
Ability to learn or recall new information.
Visual spatial NAB Figure Drawing Copy Subscale Ability to integrate visual information with motor
activities.
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